Insider Trades98 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | Sell | VCYT | Jonathan Wygant | VP, Chief Accounting Officer | 1,361 | $47.80 | $3.4B | -32.90% | +38.75% | $65.1K | -3.00% | — | Stalk |
| Jun 2, 2026 | Sell | VCYT | Phillip G. Febbo | Chief Scientific & Med Officer | 3,730 | $47.80 | $3.4B | -32.90% | +38.75% | $178.3K | -2.43% | — | Stalk |
| Jun 2, 2026 | Sell | VCYT | Annie Mcguire | EVP, General Counsel | 6,468 | $48.76 | $3.4B | -32.90% | +38.75% | $315.4K | -1.53% | 10b5-1 | Stalk |
| Jun 2, 2026 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 7,254 | $48.75 | $3.4B | -32.90% | +38.75% | $353.6K | -1.36% | 10b5-1 | Stalk |
| Jun 2, 2026 | Sell | VCYT | John Leite | Global Chief Commercial Off | 18,034 | $49.56 | $3.4B | -32.90% | +38.75% | $893.8K | -6.08% | 10b5-1 | Stalk |
| Jun 2, 2026 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 285,114 | $43.50 | $3.4B | -32.90% | +38.75% | $12.4M | -0.61% | 10b5-1 | Stalk |
| May 22, 2026 | Sell | VCYT | Jonathan Wygant | VP, Chief Accounting Officer | 48,000 | $35.10 | $3.4B | -32.90% | +38.75% | $1.7M | +0.00% | — | Stalk |
| May 6, 2026 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 10,204 | $39.02 | $3.4B | -32.90% | +38.75% | $398.2K | -3.37% | 10b5-1 | Stalk |
| Mar 4, 2026 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 5,260 | $35.19 | $3.4B | -32.90% | +38.75% | $185.1K | -4.66% | 10b5-1 | Stalk |
| Mar 4, 2026 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 6,658 | $35.55 | $3.4B | -32.90% | +38.75% | $236.7K | -3.37% | 10b5-1 | Stalk |
| Mar 4, 2026 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 18,341 | $36.14 | $3.4B | -32.90% | +38.75% | $662.9K | -6.22% | 10b5-1 | Stalk |
| Mar 4, 2026 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 45,523 | $35.97 | $3.4B | -32.90% | +38.75% | $1.6M | -5.79% | 10b5-1 | Stalk |
| Mar 2, 2026 | Sell | VCYT | Jonathan Wygant | VP, Chief Accounting Officer | 3,006 | $36.01 | $3.4B | -32.90% | +38.75% | $108.2K | -7.93% | — | Stalk |
| Mar 2, 2026 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 6,902 | $36.01 | $3.4B | -32.90% | +38.75% | $248.5K | -6.38% | — | Stalk |
| Mar 2, 2026 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 7,234 | $36.01 | $3.4B | -32.90% | +38.75% | $260.5K | -4.61% | — | Stalk |
| Mar 2, 2026 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 7,517 | $36.01 | $3.4B | -32.90% | +38.75% | $270.7K | -6.25% | — | Stalk |
| Mar 2, 2026 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 19,455 | $36.01 | $3.4B | -32.90% | +38.75% | $700.6K | -4.60% | — | Stalk |
| Mar 2, 2026 | Sell | VCYT | Phillip G. Febbo | Chief Scientific & Med Officer | 19,460 | $36.11 | $3.4B | -32.90% | +38.75% | $702.7K | -7.27% | 10b5-1 | Stalk |
| Feb 26, 2026 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 8,905 | $38.75 | $3.4B | -32.90% | +38.75% | $345.1K | -6.89% | — | Stalk |
| Feb 26, 2026 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 10,867 | $38.75 | $3.4B | -32.90% | +38.75% | $421.1K | -9.12% | — | Stalk |
| Feb 26, 2026 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 12,049 | $38.75 | $3.4B | -32.90% | +38.75% | $466.9K | -7.14% | — | Stalk |
| Feb 26, 2026 | Sell | VCYT | Phillip G. Febbo | Chief Scientific & Med Officer | 24,486 | $38.75 | $3.4B | -32.90% | +38.75% | $948.8K | -15.18% | — | Stalk |
| Feb 26, 2026 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 35,841 | $38.75 | $3.4B | -32.90% | +38.75% | $1.4M | -7.82% | — | Stalk |
| Dec 16, 2025 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 10,739 | $43.13 | $3.4B | -32.90% | +38.75% | $463.2K | -7.34% | 10b5-1 | Stalk |
| Dec 2, 2025 | Sell | VCYT | Jonathan Wygant | VP, Chief Accounting Officer | 1,325 | $46.16 | $3.4B | -32.90% | +38.75% | $61.2K | -3.42% | — | Stalk |
| Dec 2, 2025 | Sell | VCYT | Phillip G. Febbo | Chief Scientific & Med Officer | 2,955 | $46.16 | $3.4B | -32.90% | +38.75% | $136.4K | -3.20% | — | Stalk |
| Dec 2, 2025 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 4,178 | $46.57 | $3.4B | -32.90% | +38.75% | $194.6K | -2.46% | 10b5-1 | Stalk |
| Dec 2, 2025 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 4,474 | $46.52 | $3.4B | -32.90% | +38.75% | $208.1K | -1.85% | 10b5-1 | Stalk |
| Dec 2, 2025 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 15,582 | $46.62 | $3.4B | -32.90% | +38.75% | $726.4K | -1.59% | 10b5-1 | Stalk |
| Dec 2, 2025 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 16,662 | $46.70 | $3.4B | -32.90% | +38.75% | $778.2K | -4.59% | 10b5-1 | Stalk |
| Nov 25, 2025 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 2,808 | $50.00 | $3.4B | -32.90% | +38.75% | $140.4K | -3.15% | 10b5-1 | Stalk |
| Nov 7, 2025 | Sell | VCYT | Jonathan Wygant | VP, Chief Accounting Officer | 10,920 | $41.20 | $3.4B | -32.90% | +38.75% | $449.9K | -11.68% | — | Stalk |
| Nov 5, 2025 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 6,466 | $40.00 | $3.4B | -32.90% | +38.75% | $258.6K | -7.23% | 10b5-1 | Stalk |
| Nov 5, 2025 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 7,000 | $41.00 | $3.4B | -32.90% | +38.75% | $287.0K | -5.26% | 10b5-1 | Stalk |
| Oct 6, 2025 | Sell | VCYT | Phillip G. Febbo | Chief Scientific & Med Officer | 8,349 | $36.02 | $3.4B | -32.90% | +38.75% | $300.7K | -8.28% | 10b5-1 | Stalk |
| Oct 1, 2025 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 2,160 | $35.00 | $3.4B | -32.90% | +38.75% | $75.6K | -2.36% | 10b5-1 | Stalk |
| Oct 1, 2025 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 2,539 | $35.00 | $3.4B | -32.90% | +38.75% | $88.9K | -2.77% | 10b5-1 | Stalk |
| Sep 19, 2025 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 2,283 | $33.69 | $3.4B | -32.90% | +38.75% | $76.9K | -2.43% | 10b5-1 | Stalk |
| Sep 4, 2025 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 7,667 | $30.41 | $3.4B | -32.90% | +38.75% | $233.1K | -2.24% | 10b5-1 | Stalk |
| Sep 2, 2025 | Sell | VCYT | Jonathan Wygant | VP, Chief Accounting Officer | 1,648 | $30.11 | $3.4B | -32.90% | +38.75% | $49.6K | -3.40% | — | Stalk |
| Sep 2, 2025 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 2,902 | $30.11 | $3.4B | -32.90% | +38.75% | $87.4K | -3.07% | — | Stalk |
| Sep 2, 2025 | Sell | VCYT | Phillip G. Febbo | Chief Scientific & Med Officer | 2,955 | $30.11 | $3.4B | -32.90% | +38.75% | $89.0K | -2.85% | — | Stalk |
| Sep 2, 2025 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 3,507 | $30.11 | $3.4B | -32.90% | +38.75% | $105.6K | -3.60% | — | Stalk |
| Sep 2, 2025 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 5,371 | $30.11 | $3.4B | -32.90% | +38.75% | $161.7K | -3.88% | — | Stalk |
| Sep 2, 2025 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 7,914 | $30.11 | $3.4B | -32.90% | +38.75% | $238.3K | -2.26% | — | Stalk |
| Jun 4, 2025 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 2,809 | $27.20 | $3.4B | -32.90% | +38.75% | $76.4K | -2.89% | 10b5-1 | Stalk |
| Jun 2, 2025 | Sell | VCYT | Jonathan Wygant | VP, Chief Accounting Officer | 1,848 | $26.74 | $3.4B | -32.90% | +38.75% | $49.4K | -3.71% | — | Stalk |
| Jun 2, 2025 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 2,900 | $26.74 | $3.4B | -32.90% | +38.75% | $77.5K | -2.89% | — | Stalk |
| Jun 2, 2025 | Sell | VCYT | Phillip G. Febbo | Chief Scientific & Med Officer | 2,955 | $26.74 | $3.4B | -32.90% | +38.75% | $79.0K | -2.77% | — | Stalk |
| Jun 2, 2025 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 3,505 | $26.74 | $3.4B | -32.90% | +38.75% | $93.7K | -3.49% | — | Stalk |
| Jun 2, 2025 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 5,370 | $26.74 | $3.4B | -32.90% | +38.75% | $143.6K | -3.73% | — | Stalk |
| Jun 2, 2025 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 9,399 | $26.74 | $3.4B | -32.90% | +38.75% | $251.3K | -2.62% | — | Stalk |
| Mar 7, 2025 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 7,411 | $31.66 | $3.4B | -32.90% | +38.75% | $234.6K | -3.48% | 10b5-1 | Stalk |
| Mar 4, 2025 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 1,142 | $33.69 | $3.4B | -32.90% | +38.75% | $38.5K | -1.60% | 10b5-1 | Stalk |
| Mar 4, 2025 | Sell | VCYT | Phillip G. Febbo | Chief Scientific & Med Officer | 8,037 | $33.35 | $3.4B | -32.90% | +38.75% | $268.0K | -4.55% | 10b5-1 | Stalk |
| Mar 4, 2025 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 52,697 | $33.34 | $3.4B | -32.90% | +38.75% | $1.8M | -5.97% | 10b5-1 | Stalk |
| Mar 2, 2025 | Sell | VCYT | Jonathan Wygant | VP, Chief Accounting Officer | 4,301 | $34.76 | $3.4B | -32.90% | +38.75% | $149.5K | -10.55% | — | Stalk |
| Feb 27, 2025 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 13,396 | $34.37 | $3.4B | -32.90% | +38.75% | $460.4K | -8.17% | — | Stalk |
| Feb 27, 2025 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 15,255 | $34.34 | $3.4B | -32.90% | +38.75% | $523.8K | -9.17% | — | Stalk |
| Feb 27, 2025 | Sell | VCYT | Phillip G. Febbo | Chief Scientific & Med Officer | 22,426 | $34.12 | $3.4B | -32.90% | +38.75% | $765.1K | -10.66% | — | Stalk |
| Feb 27, 2025 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 22,981 | $34.28 | $3.4B | -32.90% | +38.75% | $787.9K | -8.79% | — | Stalk |
| Feb 27, 2025 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 54,597 | $34.18 | $3.4B | -32.90% | +38.75% | $1.9M | -7.62% | — | Stalk |
| Feb 3, 2025 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 527 | $43.85 | $3.4B | -32.90% | +38.75% | $23.1K | -0.46% | 10b5-1 | Stalk |
| Dec 13, 2024 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 5,590 | $43.42 | $3.4B | -32.90% | +38.75% | $242.7K | -0.90% | 10b5-1 | Stalk |
| Dec 4, 2024 | Sell | VCYT | Phillip G. Febbo | Chief Scientific & Med Officer | 3,934 | $44.09 | $3.4B | -32.90% | +38.75% | $173.4K | -4.56% | 10b5-1 | Stalk |
| Dec 4, 2024 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 18,699 | $44.02 | $3.4B | -32.90% | +38.75% | $823.2K | -20.42% | 10b5-1 | Stalk |
| Dec 2, 2024 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 1,918 | $44.12 | $3.4B | -32.90% | +38.75% | $84.6K | -2.05% | — | Stalk |
| Dec 2, 2024 | Sell | VCYT | Jonathan Wygant | VP, Chief Accounting Officer | 2,043 | $43.76 | $3.4B | -32.90% | +38.75% | $89.4K | -2.45% | — | Stalk |
| Dec 2, 2024 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 2,364 | $43.73 | $3.4B | -32.90% | +38.75% | $103.4K | -1.57% | 10b5-1 | Stalk |
| Dec 2, 2024 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 5,748 | $44.12 | $3.4B | -32.90% | +38.75% | $253.6K | -1.80% | — | Stalk |
| Dec 2, 2024 | Sell | VCYT | Phillip G. Febbo | Chief Scientific & Med Officer | 6,738 | $44.12 | $3.4B | -32.90% | +38.75% | $297.3K | -7.24% | — | Stalk |
| Dec 2, 2024 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 10,464 | $43.53 | $3.4B | -32.90% | +38.75% | $455.5K | -4.26% | 10b5-1 | Stalk |
| Nov 27, 2024 | Sell | VCYT | Jonathan Wygant | VP, Chief Accounting Officer | 5,032 | $42.89 | $3.4B | -32.90% | +38.75% | $215.8K | -10.63% | — | Stalk |
| Nov 12, 2024 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 15,275 | $38.34 | $3.4B | -32.90% | +38.75% | $585.7K | -10.93% | 10b5-1 | Stalk |
| Sep 4, 2024 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 5,479 | $29.78 | $3.4B | -32.90% | +38.75% | $163.2K | -6.71% | 10b5-1 | Stalk |
| Sep 2, 2024 | Sell | VCYT | Jonathan Wygant | VP, Chief Accounting Officer | 1,087 | $31.55 | $3.4B | -32.90% | +38.75% | $34.3K | -2.24% | — | Stalk |
| Sep 2, 2024 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 1,315 | $31.55 | $3.4B | -32.90% | +38.75% | $41.5K | -1.58% | — | Stalk |
| Sep 2, 2024 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 1,920 | $31.55 | $3.4B | -32.90% | +38.75% | $60.6K | -2.01% | — | Stalk |
| Sep 2, 2024 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 3,464 | $31.55 | $3.4B | -32.90% | +38.75% | $109.3K | -2.42% | — | Stalk |
| Sep 2, 2024 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 5,748 | $31.55 | $3.4B | -32.90% | +38.75% | $181.3K | -1.77% | — | Stalk |
| Jul 16, 2024 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 1,277 | $25.00 | $3.4B | -32.90% | +38.75% | $31.9K | -1.52% | 10b5-1 | Stalk |
| Jun 2, 2024 | Sell | VCYT | Jonathan Wygant | VP, Chief Accounting Officer | 1,087 | $20.75 | $3.4B | -32.90% | +38.75% | $22.6K | -2.22% | — | Stalk |
| Jun 2, 2024 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 1,314 | $20.75 | $3.4B | -32.90% | +38.75% | $27.3K | -1.54% | — | Stalk |
| Jun 2, 2024 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 1,919 | $20.75 | $3.4B | -32.90% | +38.75% | $39.8K | -1.97% | — | Stalk |
| Jun 2, 2024 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 3,462 | $20.75 | $3.4B | -32.90% | +38.75% | $71.8K | -2.36% | — | Stalk |
| Jun 2, 2024 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 5,746 | $20.75 | $3.4B | -32.90% | +38.75% | $119.2K | -1.74% | — | Stalk |
| Mar 15, 2024 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 2,189 | $21.10 | $3.4B | -32.90% | +38.75% | $46.2K | -1.47% | — | Stalk |
| Mar 15, 2024 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 5,971 | $21.10 | $3.4B | -32.90% | +38.75% | $126.0K | -1.78% | — | Stalk |
| Mar 2, 2024 | Sell | VCYT | Jonathan Wygant | VP, Chief Accounting Officer | 2,337 | $24.00 | $3.4B | -32.90% | +38.75% | $56.1K | -8.51% | — | Stalk |
| Mar 2, 2024 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 3,008 | $24.00 | $3.4B | -32.90% | +38.75% | $72.2K | -7.78% | — | Stalk |
| Mar 2, 2024 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 4,347 | $24.00 | $3.4B | -32.90% | +38.75% | $104.3K | -8.39% | — | Stalk |
| Mar 2, 2024 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 6,112 | $24.00 | $3.4B | -32.90% | +38.75% | $146.7K | -6.73% | — | Stalk |
| Mar 2, 2024 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 13,286 | $24.00 | $3.4B | -32.90% | +38.75% | $318.9K | -5.97% | — | Stalk |
| Dec 2, 2023 | Sell | VCYT | Jonathan Wygant | VP, Chief Accounting Officer | 507 | $26.54 | $3.4B | -32.90% | +38.75% | $13.5K | -1.84% | — | Stalk |
| Dec 2, 2023 | Sell | VCYT | John Leite | Chief Commercial Officer-CLIA | 556 | $26.54 | $3.4B | -32.90% | +38.75% | $14.8K | -1.42% | — | Stalk |
| Dec 2, 2023 | Sell | VCYT | Annie Mcguire | SVP, General Counsel | 803 | $26.54 | $3.4B | -32.90% | +38.75% | $21.3K | -1.53% | — | Stalk |
| Dec 2, 2023 | Sell | VCYT | Rebecca Chambers | Chief Financial Officer | 1,800 | $26.54 | $3.4B | -32.90% | +38.75% | $47.8K | -1.94% | — | Stalk |
| Dec 2, 2023 | Sell | VCYT | Marc Stapley | Chief Executive Officer | 3,203 | $26.54 | $3.4B | -32.90% | +38.75% | $85.0K | -1.42% | — | Stalk |